Company

Molecular Partners

As of the edition of 20 October 2026, Molecular Partners runs 5 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet1
Stopped1
Status not established3
Total5

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
HGF Hepatocyte growth factorRoute A
VEGFA Vascular endothelial growth factor A, long formRoute A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 3 trials led
  • Infections: 2 trials led
  • Lungs and airways: 2 trials led